Novel eIF4A1 inhibitors with anti-tumor activity in lymphoma.

ABSTRACT:

Background

Deregulated translation initiation is implicated extensively in cancer initiation and progression. It is actively pursued as a viable target that circumvents the dependency on oncogenic signaling, a significant factor in current strategies. Eukaryotic translation initiation factor (eIF) 4A plays an essential role in translation initiation by unwinding the secondary structure of messenger RNA (mRNA) upstream of the start codon, enabling active ribosomal recruitment on the downstream genes. Several natural product molecules with similar scaffolds, such as Rocaglamide A (RocA), targeting eIF4A have been reported in the last decade. However, their clinical utilization is still elusive due to several pharmacological limitations. In this study we identified new eIF4A1 inhibito

SUBMITTER: Kayastha F 

PROVIDER: S-EPMC9441068 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature